<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807205</url>
  </required_header>
  <id_info>
    <org_study_id>CYN20-ELITEIQ-02</org_study_id>
    <nct_id>NCT04807205</nct_id>
  </id_info>
  <brief_title>Post Market Study Using The Elite IQ Device</brief_title>
  <official_title>Post Market Study Using The Elite IQ Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open label, single-center clinical study to collect safety and&#xD;
      efficacy data on the Elite iQ workstation. The intended use of the Elite iQ device used in&#xD;
      this study is for the treatment of hair removal, pseudo folliculitis barbae, and benign&#xD;
      vascular and pigmented lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 20 subjects will be enrolled at up to 1 study center. Subjects will attend a&#xD;
      screening/pretreatment visit which may be performed on the same day as the treatment visit.&#xD;
      Subjects may receive up to 5 treatments on multiple areas of the body such as, but not&#xD;
      limited to, the face, legs, and arms. All subjects will be required to return a follow-up&#xD;
      visit at 30 - 90 days after the final treatment in each treatment area.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blinded evaluation of pre-treatment images vs. follow up images to determine which image was taken pre-treatment vs. at the follow up.</measure>
    <time_frame>60 day (+/- 30 days) post last treatment</time_frame>
    <description>Blind identification of pre-treatment images vs. 60 day follow up images. It is performed by independent reviewers. The outcome will be reported as a percentage of photographs identified correctly.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Principle Investigator assessment using the Global Aesthetic Improvement Scale (PGAIS)</measure>
    <time_frame>Baseline and 60 day (+/- 30 days) post last treatment</time_frame>
    <description>Principle Investigator assessment using the Global Aesthetic Improvement Scale (PGAIS) at the 60 day follow up visit. The GAIS scale ranges from 1 to 5, with 1 being &quot;very much improved,&quot; 2 being &quot;much improved,&quot; 3 being &quot;improved,&quot; 4 being &quot;no change,&quot; and 5 being &quot;worse.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction</measure>
    <time_frame>60 day (+/- 30 days) post last treatment</time_frame>
    <description>Subject satisfaction rates at the 60 day follow up visit. The subject satisfaction scale ranges from 1 to 6, with 1 being extremely unsatisfied, 2 being dissatisfied, 3 being slightly unsatisfied, 4 being slightly satisfied, 5 being satisfied, and 6 being extremely satisfied.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Hair Removal</condition>
  <condition>Pseudo Folliculitis Barbae</condition>
  <condition>Benign Vascular Lesion</condition>
  <condition>Pigmented Lesions</condition>
  <arm_group>
    <arm_group_label>Elite IQ Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Elite IQ will be used on multiple areas of the body such as, but not limited to, the face, legs, and arms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RF Non-Invasive Treatment</intervention_name>
    <description>Self-controlled single-arm group using the Elite IQ device</description>
    <arm_group_label>Elite IQ Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A healthy male or female 18 years of age or older.&#xD;
&#xD;
          -  Understands and accepts obligation not to receive any other procedures on the&#xD;
             treatment area through the length of the study.&#xD;
&#xD;
          -  Understands and accepts the obligation and is logistically able to be present for all&#xD;
             visits.&#xD;
&#xD;
          -  Is willing to comply with all requirements of the study and sign the informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is hypersensitive to light in the near infrared wavelength region&#xD;
&#xD;
          -  The subject has sun-damaged skin (treatment contraindicated with Alex laser only)&#xD;
&#xD;
          -  The subject had recent unprotected sun exposure (for Alex laser within four weeks of&#xD;
             treatment; for Nd:YAG laser within one week of treatment), including the use of&#xD;
             tanning beds or tanning products, such as creams, lotions and sprays&#xD;
&#xD;
          -  The subject is taking medication which is known to increase sensitivity to sunlight&#xD;
&#xD;
          -  The subject has seizure disorders triggered by light&#xD;
&#xD;
          -  The subject is taking anticoagulants&#xD;
&#xD;
          -  The subject is taking or have taken oral isotretinoin, such as AccutaneÂ®, within the&#xD;
             last six months&#xD;
&#xD;
          -  The subject is taking medication that alters the wound-healing response&#xD;
&#xD;
          -  The subject has a history of healing problems or history of keloid formation&#xD;
&#xD;
          -  The subject has an active localized or systemic infection, or an open wound in area&#xD;
             being treated&#xD;
&#xD;
          -  The subject has a significant systemic illness or an illness localized in area being&#xD;
             treated&#xD;
&#xD;
          -  The subject has a history of skin cancer or suspicious lesions&#xD;
&#xD;
          -  The subject has an autoimmune disease&#xD;
&#xD;
          -  The subject is receiving or have received gold therapy&#xD;
&#xD;
          -  The subject is currently enrolled in an investigational drug or device trial, or has&#xD;
             received an investigational drug or been treated with an investigational device within&#xD;
             in the area to be treated 6 months to entering this study.&#xD;
&#xD;
          -  The subject has any condition or is in a situation which in the investigators opinion&#xD;
             may put the subject at significant risk, may confound study results or may interfere&#xD;
             significantly with the subject's participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Civiok</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic Carmel Valley</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folliculitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

